Hua Medicine (Shanghai) Company Description

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China.

The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD.

It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease.

Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China.

Hua Medicine (Shanghai) Ltd.

Country	Cayman Islands
Founded	2011
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	168
CEO	Li Chen

Contact Details

Address: Hua Medicine, Building 2, Lane 36 Shanghai, 201203 China
Phone	86 21 3810 1800
Website	huamedicine.com

Stock Details

Ticker Symbol	2552
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	KYG4644K1022
SIC Code	2836

Key Executives

Name	Position
Dr. Li Chen Ph.D.	Founder, Chief Executive Officer and Executive Director
Dr. Yi Zhang M.D., Ph.D.	Senior Vice President of Pharma Development, Chief Medical Officer ? China and Executive Director
Chien Cheng Lin J.D.	Executive Vice President and Chief Strategy Officer
Dr. Fuxing Tang Ph.D.	Chief Technology Officer, Vice President of Chemical Manufacturing Control Department and Head of Research & Development in USA
Dr. Changhong Li Ph.D.	Chief Scientific Officer
Chengde Wang	Head of IR
Yu Lu	Vice President of Sales and Marketing
Ying Xie M.B.A.	Vice President of Quality Assurance Division and Chief Quality Officer
Wing Yan Yuen FCIS, FCS	Company Secretary